GR3024271T3 - Interleukin-4 receptors - Google Patents

Interleukin-4 receptors

Info

Publication number
GR3024271T3
GR3024271T3 GR970401920T GR970401920T GR3024271T3 GR 3024271 T3 GR3024271 T3 GR 3024271T3 GR 970401920 T GR970401920 T GR 970401920T GR 970401920 T GR970401920 T GR 970401920T GR 3024271 T3 GR3024271 T3 GR 3024271T3
Authority
GR
Greece
Prior art keywords
receptors
interleukin
mammalian
dnas
products
Prior art date
Application number
GR970401920T
Other languages
English (en)
Inventor
David J Cosman
Linda Park
Bruce Mosley
Patricia Beckmann
Carl J March
Rejean Idzerda
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of GR3024271T3 publication Critical patent/GR3024271T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GR970401920T 1988-10-31 1997-07-30 Interleukin-4 receptors GR3024271T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26504788A 1988-10-31 1988-10-31
US31943889A 1989-03-02 1989-03-02
US32615689A 1989-03-20 1989-03-20
US37092489A 1989-06-23 1989-06-23

Publications (1)

Publication Number Publication Date
GR3024271T3 true GR3024271T3 (en) 1997-10-31

Family

ID=27500837

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970401920T GR3024271T3 (en) 1988-10-31 1997-07-30 Interleukin-4 receptors

Country Status (14)

Country Link
US (10) US5840869A (el)
EP (1) EP0367566B1 (el)
JP (1) JP2744821B2 (el)
AT (1) ATE153068T1 (el)
AU (1) AU643427B2 (el)
DE (1) DE68928043T2 (el)
DK (1) DK175583B1 (el)
ES (1) ES2103706T3 (el)
FI (1) FI106044B (el)
GR (1) GR3024271T3 (el)
IE (1) IE61013B1 (el)
IL (1) IL91705A (el)
NZ (1) NZ231189A (el)
WO (1) WO1990005183A1 (el)

Families Citing this family (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
EP0490975A1 (en) * 1989-09-07 1992-06-24 Schering Corporation Interleukin-4 receptors
DK0417563T3 (da) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
AU635377B2 (en) * 1989-11-21 1993-03-18 University Of Melbourne, The Anti-inflammatory compositions and methods
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3122139B2 (ja) * 1991-10-15 2001-01-09 マラーキー，ミッシェル，エフ． 後期段階炎症反応の治療用組成物
EP0615546A1 (en) * 1991-11-27 1994-09-21 Schering Corporation Region of cytoplasmic domain of the human interleukin-4 receptor, as antagonists of il-4
DE4322330A1 (de) * 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
DE4228839A1 (de) * 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
JPH08508035A (ja) * 1993-03-19 1996-08-27 イミュネックス・コーポレーション 可溶性レセプターと複合化したリガンドを含む医薬組成物
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5591825A (en) * 1994-07-05 1997-01-07 Tularik, Inc. Interleukin 4 signal transducers
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
DK0835305T3 (da) 1995-06-29 2006-02-13 Immunex Corp Cytokin som inducerer apoptose
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) * 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7078494B1 (en) * 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US6605271B2 (en) * 1996-08-23 2003-08-12 Human Genome Sciences, Inc. T1 receptor-like ligand II and uses thereof
US6586210B1 (en) * 1996-08-23 2003-07-01 Human Genome Sciences, Inc. Polynucleotides encoding T1 receptor like ligand II
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
AU1126099A (en) * 1997-10-29 1999-05-17 Genentech Inc. Polypeptides and nucleic acids encoding the same
US6703488B1 (en) * 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
US6630140B1 (en) * 1998-03-10 2003-10-07 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
ATE332373T1 (de) 1998-08-21 2006-07-15 Immunex Corp Menschlisches il-1 epsilon dna und polypeptide
EP1939297A1 (en) 1998-09-24 2008-07-02 Pharmacia & Upjohn Company LLC Alzheimer's disease secretase
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
PT1141286E (pt) 1998-12-14 2007-01-31 Genetics Inst Llc Cadeia de receptores de citocina
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US6693172B1 (en) 1999-05-27 2004-02-17 Pharmacia And Upjohn Company Double mutant alpha-7 nicotinic acetylcholine receptor
US6455290B1 (en) 1999-07-09 2002-09-24 Pharmacia Italia S.P.A. Tankyrase homolog protein (THP), nucleic acids, and methods related to the same
AU2000263446A1 (en) * 1999-07-13 2001-01-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 4 receptor alpha gene
CA2388599A1 (en) 1999-10-22 2001-05-03 Pharmacia & Upjohn Company Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
JP2003516164A (ja) * 1999-12-10 2003-05-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｔ１レセプター様リガンドｉｉおよびこれの使用
WO2001045730A2 (en) 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
EP1158058A1 (en) * 2000-05-19 2001-11-28 Centre National De La Recherche Scientifique Compositions and methods suitable for nucleic acid analyses
AU2001274894A1 (en) 2000-05-22 2001-12-03 Pharmacia And Upjohn Company Novel matrix metalloproteinases
AU2001272925A1 (en) 2000-05-26 2001-12-11 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
US7259244B2 (en) 2000-06-16 2007-08-21 Nerviano Medical Sciences S.R.L. Human homologue of the DBF4/ASK1 protein, nucleic acids, and methods related to the same
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
AU2001271839A1 (en) 2000-07-05 2002-01-14 Pharmacia And Upjohn Company Human ion channels
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
ES2281458T3 (es) * 2000-12-21 2007-10-01 Nektar Therapeutics Composiciones de polvo estables en almacenamiento del receptor de interleucina 4.
EP3467117B1 (en) * 2001-09-20 2020-07-15 Immunex Corporation Selection of cells expressing heteromeric polypeptides
PL373594A1 (en) 2001-10-04 2005-09-05 Immunex Corporation Ul16 binding protein 4
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
AU2003220529B2 (en) 2002-03-27 2006-09-07 Immunex Corporation Methods for increasing polypeptide production
DK1408106T3 (da) * 2002-10-11 2007-06-11 Sentoclone Ab Cancer immunterapi
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
CN100549163C (zh) 2002-12-16 2009-10-14 技术研究及发展基金有限公司 制备无饲养细胞、无异源的人胚胎干细胞的方法以及使用该方法制备的干细胞培养物
CA2512808A1 (en) * 2003-01-18 2004-08-12 Marc Elliot Rothenberg Regulation of allergen induced gene
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2007500132A (ja) 2003-07-25 2007-01-11 アムジェン インコーポレイテッド Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法
CA2543982C (en) 2003-11-07 2013-01-08 Immunex Corporation Antibodies that bind interleukin-4 receptor
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
PT2805728T (pt) * 2003-12-23 2020-04-08 Genentech Inc Novos anticorpos anti-il13 e o uso dos mesmos
CA2554596A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypetides and therapeutic uses thereof
ATE465172T1 (de) 2004-03-05 2010-05-15 Univ Illinois Peptidträger für die verabreichung von arzneimitteln
US7319015B2 (en) 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en) 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
WO2005094879A2 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human ox40l (cd 134l)
WO2005116069A2 (en) 2004-04-14 2005-12-08 Monell Chemical Senses Center Taste receptors of the t1r family from domestic dog
EA013071B1 (ru) 2004-04-23 2010-02-26 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи Способ получения вируса репродуктивно-респираторного синдрома свиней (pprsv) и способ получения pprsv вакцины
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
EP1909831A4 (en) * 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
KR20070009269A (ko) 2005-07-15 2007-01-18 한국생명공학연구원 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
CA2627446A1 (en) * 2005-11-21 2007-05-31 Laboratoires Serono S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
AU2006328945B2 (en) * 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
WO2007071410A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating urinary bladder cancer
WO2007071389A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating disseminated cancer
EP1966369B1 (en) * 2005-12-21 2010-10-06 Sentoclone AB Method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
US8129334B2 (en) 2006-03-31 2012-03-06 The Regents Of The University Of California Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory
RU2009101783A (ru) 2006-06-21 2010-07-27 Апогеникс Гмбх (De) Дифференциальная экспрессия цитокинов il-4 и/или il-10 в злокачественной опухоли человека
EP2049147A2 (en) * 2006-07-06 2009-04-22 Apogenix GmbH Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
EP2074139B1 (en) 2006-09-08 2013-10-23 Amgen, Inc Il-1 family variants
WO2008033517A2 (en) 2006-09-13 2008-03-20 Abbott Laboratories Cell culture improvements
EP2500416A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
PL2769992T3 (pl) 2006-10-02 2021-08-02 Regeneron Pharmaceuticals, Inc. Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008131376A2 (en) * 2007-04-23 2008-10-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
CA2696761C (en) 2007-08-21 2017-02-14 Amgen Inc. Human c-fms antigen binding proteins
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
EP2245064B1 (en) * 2007-12-21 2014-07-23 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
GB0803076D0 (en) 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2113262B1 (en) * 2008-04-29 2013-11-06 Proxy Biomedical Limited A Tissue Repair Implant
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
JP2011526916A (ja) 2008-06-30 2011-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 全身性紅斑性狼瘡を同定および処置するための診断標的および治療標的としてのリソソームホスホリパーゼａ２（ｌｐｌａ２）活性
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
US20100015161A1 (en) * 2008-07-18 2010-01-21 Sentoclone Ab Composition Comprising In Vitro Expanded T-Lymphocytes and Vessel Formation Inhibitors Suitable in the Treatment of Cancer
US8815794B2 (en) 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
JP5524977B2 (ja) 2008-12-04 2014-06-18 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 高分泌性蛋白質のスクリーニングおよび組換え蛋白質の生産のための融合パートナーとしてのその用途
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US20120076754A1 (en) 2009-05-20 2012-03-29 Ziad Mallat Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20120311728A1 (en) 2009-11-06 2012-12-06 Ziad Mallat Methods and pharmaceutical composition for the treatment of atherosclerosis
MX2012005527A (es) 2009-11-13 2012-08-08 Grifols Therapeutics Inc Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011089152A1 (en) 2010-01-20 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity
WO2011127418A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
AR082461A1 (es) 2010-08-03 2012-12-12 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG187198A1 (en) 2010-08-05 2013-03-28 Amgen Inc Dipeptides to enhance yield and viability from cell cultures
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012042289A1 (en) 2010-09-28 2012-04-05 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of bone density related diseases
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
US20140086895A1 (en) 2011-05-10 2014-03-27 Universite De Rouen Methods and pharmaceutical compositions for the treatment of autoimmune diseases
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2535714A1 (en) * 2011-06-16 2012-12-19 Istituto Nazionale Di Genetica Molecolare-INGM Biomarkers for autoimmune liver diseases and uses thereof
LT2837680T (lt) 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
WO2013009971A1 (en) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
BR112014004591A2 (pt) 2011-09-02 2017-03-28 Amgen Inc produto farmacêutico de análise da exposição à luz de um produto farmacêutico
ES2806146T3 (es) 2011-09-22 2021-02-16 Amgen Inc Proteínas de unión al antígeno CD27L
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
EP2596802A1 (en) 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
ES2638649T3 (es) 2011-11-28 2017-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento
CN104220460A (zh) 2011-12-08 2014-12-17 安姆根有限公司 激动人lcat抗原结合蛋白和它们在疗法中的用途
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
WO2013106577A2 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
RU2650800C2 (ru) 2012-04-27 2018-04-17 Ново Нордиск А/С Белки, связывающие антиген - лиганд cd30 человека
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
WO2013182650A1 (en) 2012-06-06 2013-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of cancer
EP2674168A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Modulation of effector T cell responses by local depletion of complement component C3
US20150166630A1 (en) 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof
PT3470432T (pt) 2012-08-21 2021-12-14 Regeneron Pharma Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AU2013354937B2 (en) 2012-12-07 2019-09-19 North Carolina State University Beta-hexosyl-transferases and uses thereof
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014159441A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Removal of leaked affinity purification ligand
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
AU2014244444A1 (en) 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
AU2014228924B2 (en) 2013-03-15 2019-04-18 Amgen Inc. Human PAC1 antibodies
CN110511279B (zh) 2013-05-30 2024-03-29 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
US10059771B2 (en) 2013-06-21 2018-08-28 Sanofi Biotechnology Methods for treating nasal polyposis by administering an IL-4R antagonist
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
WO2015048272A1 (en) 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
US11130980B2 (en) 2013-10-31 2021-09-28 Amgen Inc. Use of monensin to regulate glycosylation of recombinant proteins
WO2015086727A2 (en) 2013-12-11 2015-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method for patients suffering of a cancer
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CN112481337A (zh) 2014-01-13 2021-03-12 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
EA202190244A3 (ru) 2014-01-29 2021-08-31 Эмджен Инк. Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
RU2019119857A (ru) 2014-02-20 2019-07-12 Аллерган, Инк. Антитела к компоненту комплемента c5
KR102368450B1 (ko) 2014-02-21 2022-02-28 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한 천식의 치료 또는 예방 방법
WO2015130826A1 (en) 2014-02-27 2015-09-03 Allergan, Inc. COMPLEMENT FACTOR Bb ANTIBODIES
MX2016011132A (es) 2014-02-28 2016-12-08 Regeneron Pharma Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
NO2785538T3 (el) 2014-05-07 2018-08-04
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
ES2709994T3 (es) 2014-06-04 2019-04-22 Amgen Inc Métodos de recolección en cultivos de células de mamífero
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
MX2017006463A (es) 2014-11-19 2018-04-20 Amgen Inc Cuantificacion de porcion de glicano en glicoproteinas recombinantes.
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AU2016215155A1 (en) 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
EP3254104B1 (en) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
CA3232537A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016323440B2 (en) 2015-09-15 2023-07-13 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
CN108138147B (zh) 2015-09-22 2022-11-01 豪夫迈·罗氏有限公司 含Fc蛋白的表达
BR112018007356A2 (pt) 2015-11-02 2018-10-23 Genentech Inc métodos de produção de formas fucosiladas e não fucosiladas de uma proteína
EP3390447A1 (en) 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
PE20181327A1 (es) 2015-12-23 2018-08-20 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
JP7422480B2 (ja) 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
CN109563125B (zh) 2016-07-22 2022-08-09 美国安进公司 含有Fc的蛋白的纯化方法
MA46098A (fr) 2016-09-01 2019-07-10 Regeneron Pharma Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
US20180110856A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical Formulations and Methods of Making the Same
AU2017356317A1 (en) 2016-11-14 2019-05-30 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
TW202332696A (zh) 2016-12-01 2023-08-16 美商再生元醫藥公司 治療發炎症狀的方法
AU2018206279B2 (en) 2017-01-06 2020-09-03 Abl Bio Inc. Anti-alpha-syn antibody and use thereof
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US11970526B2 (en) 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
CR20190532A (es) 2017-06-20 2020-01-10 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2019020480A1 (en) 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
EP3661562A1 (en) 2017-08-04 2020-06-10 Amgen Inc. Method of conjugation of cys-mabs
CN111526920A (zh) 2017-10-30 2020-08-11 赛诺菲生物技术公司 通过施用il-4r拮抗剂来治疗或预防哮喘的方法
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
JP2022502454A (ja) 2018-10-04 2022-01-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 認知機能を回復又は改善するための方法
WO2020074005A1 (en) * 2018-10-12 2020-04-16 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric genes
BR112021011063A2 (pt) 2018-12-10 2021-08-31 Amgen Inc. Transposase piggybac mutada
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
MX2021014534A (es) 2019-05-30 2022-02-11 Amgen Inc Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos.
US20220363770A1 (en) 2019-06-28 2022-11-17 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
AU2020328038A1 (en) 2019-08-13 2022-03-31 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
EP4054590A1 (en) 2019-11-04 2022-09-14 Amgen Inc. Methods for treating leukemia
CA3160482A1 (en) 2019-11-08 2021-05-14 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
CA3160438A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
KR20220114595A (ko) 2019-12-17 2022-08-17 암젠 인크 치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제
CA3164129A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022040466A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
US20230374162A1 (en) 2020-10-07 2023-11-23 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
TW202233660A (zh) 2020-10-30 2022-09-01 美商安進公司 過表現胰島素樣生長因子受體突變體以調節ｉｇｆ補充
AU2021379598A1 (en) 2020-11-10 2023-06-08 Amgen Inc. Novel linkers of multispecific antigen binding domains
EP4326761A1 (en) 2021-04-20 2024-02-28 Amgen Inc. Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
EP4330281A1 (en) 2021-04-29 2024-03-06 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2022261299A1 (en) 2021-06-10 2022-12-15 Amgen Inc. Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3
TW202328442A (zh) 2021-09-10 2023-07-16 美商安進公司 平臺宿主對ｉｇｆ—培養基之適應
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023129974A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023172965A1 (en) 2022-03-09 2023-09-14 Amgen Inc. Optimized transfection protocol
WO2023175022A1 (en) 2022-03-16 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat infectious diseases
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US20240024472A1 (en) 2022-05-02 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations
WO2023215750A2 (en) 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) * 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
HU211059B (en) * 1988-02-02 1995-10-30 Schering Biotech Corp Method for producing pharmaceutical compositions usable for reducing immunglobulin e responses, containing human il-4 antibodies
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
KR0172123B1 (ko) * 1989-03-07 1999-02-01 게르하르트 후버; 루돌프 호프만 재조합 단백질 수용체
EP0490975A1 (en) * 1989-09-07 1992-06-24 Schering Corporation Interleukin-4 receptors
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
EP0615546A1 (en) * 1991-11-27 1994-09-21 Schering Corporation Region of cytoplasmic domain of the human interleukin-4 receptor, as antagonists of il-4
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
JPH08508035A (ja) * 1993-03-19 1996-08-27 イミュネックス・コーポレーション 可溶性レセプターと複合化したリガンドを含む医薬組成物

Also Published As

Publication number Publication date
DK78491A (da) 1991-04-30
ES2103706T3 (es) 1997-10-01
DK78491D0 (da) 1991-04-29
NZ231189A (en) 1991-06-25
US20050118176A1 (en) 2005-06-02
US20030185821A1 (en) 2003-10-02
US5717072A (en) 1998-02-10
AU643427B2 (en) 1993-11-18
US6548655B1 (en) 2003-04-15
WO1990005183A1 (en) 1990-05-17
IL91705A (en) 1998-12-27
IL91705A0 (en) 1990-06-10
IE61013B1 (en) 1994-09-07
US6716587B2 (en) 2004-04-06
FI912064A0 (fi) 1991-04-29
EP0367566B1 (en) 1997-05-14
EP0367566A1 (en) 1990-05-09
AU4411389A (en) 1990-05-28
DE68928043D1 (de) 1997-06-19
US5599905A (en) 1997-02-04
US5840869A (en) 1998-11-24
IE893027L (en) 1990-04-30
JP2744821B2 (ja) 1998-04-28
US6391581B1 (en) 2002-05-21
US5856296A (en) 1999-01-05
US7317090B2 (en) 2008-01-08
US5767065A (en) 1998-06-16
ATE153068T1 (de) 1997-05-15
DK175583B1 (da) 2004-12-13
US20090226472A1 (en) 2009-09-10
DE68928043T2 (de) 1997-09-11
JPH02215385A (ja) 1990-08-28
FI106044B (fi) 2000-11-15

Similar Documents

Publication Publication Date Title
GR3024271T3 (en) Interleukin-4 receptors
EP0318296A3 (en) Interleukin-1 receptors
IE902158L (en) Interleukin-7 Receptors
ZA887773B (en) Interleukin-7
LU90591I2 (fr) Enbrel-etanercept
IL98205A0 (en) Type ii interleukin-1 receptors
AU2872089A (en) Receptor protein for human b cell stimulatory factor-2
AU6733487A (en) Mammalian interleukin-4
DK0494260T3 (da) Receptorer for granulocytkolonistimulerende faktor